Approved Immunology & Autoimmune Deal Benchmarks
Market Analysis
Approved immunology & autoimmune licensing deals carry a median total deal value of $7.4B, with upfront payments ranging from $2.1B to $3.5B. At this stage, deal structures are shifted toward higher upfront allocations, reflecting reduced regulatory risk and near-term commercial potential. The recommended split allocates 39% to upfront and 61% to milestones.
The immunology & autoimmune landscape at the approved stage is characterized by high competitive intensity, particularly in inflammatory bowel disease and autoimmune conditions. Development milestones average $226M, regulatory milestones contribute $904M, and commercial milestones reach $3.4B. CAR-T for autoimmune diseases, TL1A inhibitors, and next-generation targeted therapies are reshaping the licensing landscape.
Royalty rates for approved immunology & autoimmune deals range from 21.9% to 30% at the base tier, with high-tier escalation to 35%. The reduced risk profile at this stage justifies higher fixed royalty commitments.
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
What is the average upfront payment for approved immunology & autoimmune deals?
How are approved immunology & autoimmune deal milestones structured?
What royalty rates are typical for approved immunology & autoimmune licensing?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.
Start CalculatingNeed the full deal landscape?
The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.